<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">87537</article-id><article-id pub-id-type="doi">10.7554/eLife.87537</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Osteonecrosis in Gaucher Disease in the era of multiple therapies: biomarker set for risk stratification from a tertiary referral center</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-309864"><name><surname>Basiri</surname><given-names>Mohsen</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9592-4059</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310408"><name><surname>Ghaffari</surname><given-names>Mohammad E</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278316"><name><surname>Ruan</surname><given-names>Jiapeng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310409"><name><surname>Murugesan</surname><given-names>Vagishwari</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310410"><name><surname>Kleytman</surname><given-names>Nathaniel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278309"><name><surname>Belinsky</surname><given-names>Glenn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310411"><name><surname>Akhavan</surname><given-names>Amir</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310412"><name><surname>Lischuk</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310413"><name><surname>Guo</surname><given-names>Lilu</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-278321"><name><surname>Klinger</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-262226"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3447-6421</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><institution content-type="dept">Department of Internal Medicine</institution>, <institution>Yale University</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of ENT, Head and Neck Surgery</institution>, <institution>Guilan University of Medical Sciences</institution>, <addr-line><named-content content-type="city">Rasht</named-content></addr-line>, <country>Islamic Republic of Iran</country></aff><aff id="aff3"><institution content-type="dept">Department of Rheumatology</institution>, <institution>University of Toronto</institution>, <addr-line><named-content content-type="city">Toronto</named-content></addr-line>, <country>Canada</country></aff><aff id="aff4"><institution content-type="dept">Department of Computer and Information Science</institution>, <institution>University of Massachusetts Dartmouth</institution>, <addr-line><named-content content-type="city">Dartmouth</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Radiology and Biomedical Imaging</institution>, <institution>Yale University</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Translational Sciences</institution>, <institution>Sanofi</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">Translational Sciences</institution>, <institution>Sanofi</institution>, <addr-line><named-content content-type="city">Framingham</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-190571"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing editor</role><aff><institution>DaVita Labs</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>pramod.mistry@yale.edu</email> (PM);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>05</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e87537</elocation-id><history><date date-type="received"><day>08</day><month>03</month><year>2023</year></date><date date-type="accepted"><day>22</day><month>05</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Basiri et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Basiri et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-87537-v1.pdf"/><abstract><p><bold>Background:</bold> A salutary effect of treatments for Gaucher disease (GD) has been reduction in the incidence of avascular osteonecrosis (AVN). However, there are reports of AVN in patients receiving enzyme replacement therapy (ERT), and it is not known whether it is related to individual treatments, <italic>GBA</italic> genotypes, phenotypes, biomarkers of residual disease activity or anti-drug antibodies.</p><p><bold>Objective:</bold> Prompted by development of AVN in several patients receiving ERT, we aimed to delineate the determinants of AVN in patients receiving ERT or eliglustat substrate reduction therapy (SRT) during 20 years in a tertiary referral center.</p><p><bold>Methods:</bold> Longitudinal follow-ups of 155 GD patients between 2001 and 2021, were analyzed for episodes of AVN on therapy, type of therapy, <italic>GBA1</italic> genotype, spleen status, biomarkers, and other disease indicators. We applied mixed-effects logistic model to delineate the independent correlates of AVN while receiving treatment.</p><p><bold>Results:</bold> The patients received cumulative 1382 years of treatment. There were 16 episodes of AVN in 14 patients, with two episodes, each occurring in two patients. Heteroallelic p.Asn409Ser GD1 patients were 10 times (95% CI,1.5 - 67.2) more likely than p.Asn409Ser homozygous patients to develop osteonecrosis during treatment. History of AVN prior to treatment initiation was associated with 4.8-fold increased risk of AVN on treatment (95% CI, 1.5-15.2). The risk of AVN among patients receiving velaglucerase ERT was 4.68 times higher compared to patients receiving imiglucerase ERT (95% CI,1.67-13). No patient receiving eliglustat SRT suffered AVN. There was a significant correlation between GlcSph levels and AVN. Together, these biomarkers reliably predicted risk of AVN during therapy (ROC AUC 0.894, p&lt;0.001).</p><p><bold>Conclusions:</bold> There is a low, but significant risk of AVN in GD in the era of ERT/SRT. We found increased risk of AVN was related to <italic>GBA</italic> genotype, history of AVN prior to treatment initiation, residual serum GlcSph level, and the type of ERT. No patient receiving SRT developed AVN. These findings exemplify a new approach to biomarker applications in a rare inborn error of metabolism to evaluate clinical outcomes in comprehensively followed patients and will aid identification of GD patients at higher risk of AVN who will benefit from closer monitoring and treatment optimization.</p><p><bold>Funding:</bold> LSD Training Fellowship from Sanofi to MB.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100013995</institution-id><institution>Sanofi Genzyme</institution></institution-wrap></funding-source><award-id>LSD Training Fellowship from Sanofi to MB</award-id><principal-award-recipient><name><surname>Basiri</surname><given-names>Mohsen</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Lilu Guo, is an employee of Sanofi and may hold stocks..</p></fn><fn fn-type="conflict" id="conf3"><p>Katherine Klinger, is an employee of Sanofi and may hold stocks..</p></fn><fn fn-type="conflict" id="conf4"><p>Pramod K Mistry, Reviewing editor, <italic>eLife</italic>PKM receives a research grant from Sanofi and has received travel support from Sanofi..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: All participants were enrolled in our observational studies approved by Yale's IRB. Patients also were provided with verbal explanations and their data were collected after signing consent forms.HIC#0209021074HIC#1005006783</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>This observational study is approved by Yale University IRB and each patient provided informed consent. The patients have not provided consent to sharing their data with other investigators. Interested academic, non-commercial researchers can contact the Senior Corresponding author, Dr Pramod Mistry at Pramod.mistry@yale.edu to discuss the request to access original data. They do not need to apply or submit a project proposal. All statistical analyses were performed with SPSS version 28 (SPSS Inc., Chicago, IL, USA). MedCalc version 20.026 was used for ROC curve analysis and graphs were plotted by GraphPad Prism version 9.3.1.We do not have consent to share individual patient data. Even de-identified data risks identification through age and GBA genotype information, thus violating HIPPA patient confidentiality. Upon request to the Senior Corresponding author, the PI, we will share processed version of datasets.</p></sec></sec></back></article>